Multicentric Castleman's disease and Kaposi's sarcoma in a HIV-positive patient on highly active antiretroviral therapy

Lauro Ortega,1 Chad J. Cooper,1 Salman Otoakesh,1 Mona Mojtahedzadeh,2 Claudia S. Didia,2 Alireza Torabi,2 Zeina Nahleh1
1Department of Internal Medicine, Texas Tech University Health Sciences Center; 2Department of Neuroscience Research Center, Paul L. Foster School of Medicine, Texas Tech University; 3Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA

Abstract

Castleman’s disease is a group of rare lymphoproliferative disorders. The plasmablastic multicentric Castleman’s disease is frequently discovered in HIV-infected individuals in association with Kaposi sarcoma (HHV-8). Thirty-five year old male presented to our care with the main complaint of severe back pain for one week. His past medical problems include acquired immune deficiency syndrome diagnosed 12 years prior and Kaposi sarcoma, currently on highly active antiretroviral therapy (HAART). Radiographic imaging revealed hepatomegaly and diffuse lymphadenopathy. The HIV viral load was <20 polymerase chain reaction copies/mL, absolute CD4 count was 453 cells/mcL (490-1740 cells/mcL) and CD8 count was 4142 cells/mcL (180-1170 cells/mcL). Excisional biopsy of the left supraclavicular lymph node was performed with pathological findings of HHV8+ Kaposi sarcoma in the background of multicentric Castleman’s disease (plasmacytic variant). No evidence of transformation into large B-cell or plasmablastic lymphoma was noted. He was discharged on HAART and follow up to receive chemotherapy with cyclophosphamide, adriamycin, vincristine plus prednisone was started and rituximab plus prophylaxis for pneumocystis carinii. Multicentric Castleman’s disease has become more relevant in recent years due to its association with HIV and HHV-8 (Kaposi sarcoma) and its potential to progress into plasmablastic B-cell lymphoma. The progression of MCD to B-cell lymphoma is a concern, especially in patients with HIV infection because it presents the worst outcome and a high mortality, despite treatment. The most intriguing part of this case is that MCD occurred in a HIV-positive on HAART. This case signals a warning that a high suspicion for MCD can be justified even in those HIV-positive patients on HAART because the possibly of progression to plasmablastic B-cell lymphoma.

Introduction

Castleman’s disease (CD) is a group of rare lymphoproliferative disorders with heterogeneous manifestations that range from being asymptomatic to recurrent episodes of widespread lymphadenopathy with systemic symptoms.1 CD is classified as either localized (unicentric) or generalized (multicentric) lymphadenopathy. CD is further divided into variants based on the characteristic lymph node findings. Three variants have been described, hyaline vascular, plasma cell or mixed. The hyaline vascular variant is the most common type of CD and accounts for 70% of cases and is equally distributed among both genders.2 A single node or chain of lymph nodes is involved, most commonly in the mediastinum. The plasma cell variant represents 10-20% of cases.2 This variant will have constitutional symptoms and enlarged lymph nodes.

The hyaline-vascular variant is characterized by abnormal follicles with regressed germinal centers surrounded by widened mantle zones composed of small lymphocytes in an onion ring-like arrangement.2 The plasma cell variant has a hyperplastic germinal center and a large accumulation of polyclonal plasma cells in the interfollicular area.2 The mixed variant, demonstrates the presence of both hyaline vascular and plasma cell characteristics. The plasma cell type has been further defined into a less common subvariant form that is characterized by large plasmablasts harboring human herpesvirus-8 (HHV-8) with the potential to progress to plasmablastic monoclonal lymphoma.3,4 This subvariant has an outer mantle zone of the follicles with an increased number of plasmablasts. The HHV-8 plasmablasts can rapidly multiply and coalesce to form microlymphomas that eventually could progress to plasmablastic B-cell lymphoma.2-5 The plasmablastic multicentric Castleman’s disease (MCD) is multifocal, aggressive and is associated with polynuropathy, organomegaly, endocrinopathy, monoclonal gammapathy and skin changes (POEMS).6,7 This type is frequently found in HIV-infected individuals. It is clinically characterized by severe inflammatory symptoms attributable to disarray in cytokines such as elevations in interleukin-6 (IL-6) and interleukin1-10 (IL-10).8 The clinical presentation of MCD is more varied and commonly features fever, night sweats, anorexia, hepatosplenomegaly, weight loss, or failure to thrive.2 The amount of HHV8 in peripheral blood mononuclear cells or plasma cells has been noted to correspond with symptoms during MCD flare.1,5 Laboratory abnormalities could include an elevated acute phase reactants, anaemia, hypoalbuminemia, polyclonal hyperglobulinemia, elevated transaminases and renal disease.2,5,7

Dispensieri et al.4 analyzed the clinical spectrum of Castleman’s disease in 113 patients. Fifty-four patients had plasma cell variant, 54 with hyaline vascular variant and 5 with mixed variant histology. Sixty (53%) of the 113 patients had multicentric disease. Patients with hyaline vascular disease were more likely to have unicentric disease. Patients with plasma cell variant more commonly had multicentric disease. Patients with MCD were more likely to be older, have B-symptoms, enlarged palpable lymph nodes, peripheral neuropathy, extravascular volume overload, POEMS syndrome, anemia, leukocytosis, thrombocytosis, elevated acute phase reactants, hypergammaglobulinemia, hypoalbuminemia and an elevated creatinine.8 We present a case of young Hispanic male with MCD secondary to HIV and HHV-8 infection that was on highly active antiretroviral therapy (HAART), had a low HIV viral load and CD4 count of 453 cells/mcL.

Case Report

Thirty-five year old Hispanic male presented to our care with the main compliant of severe intermittent mid to lower back pain that had progressively worsened since 1 week. The back pain was associated with a fever, night sweats, and anorexia. He was admitted for a blood and urine culture which were negative. The patient was started on highly active antiretroviral therapy (HAART) and followed up to receive chemotherapy with cyclophosphamide, adriamycin, vincristine plus prednisone was started and rituximab plus prophylaxis for pneumocystis carinii. Multicentric Castleman’s disease has become more relevant in recent years due to its association with HIV and HHV-8 (Kaposi sarcoma) and its potential to progress into plasmablastic B-cell lymphoma. The progression of MCD to B-cell lymphoma is a concern, especially in patients with HIV infection because it presents the worst outcome and a high mortality, despite treatment. The most intriguing part of this case is that MCD occurred in a HIV-positive patient on HAART. This case signals a warning that a high suspicion for MCD can be justified even in those HIV-positive patients on HAART because the possibly of progression to plasmablastic B-cell lymphoma.

Correspondence: Chad J. Cooper, Department of Internal Medicine, Texas Tech University Health Sciences Center, 4800 Alberta Ave, El Paso, TX, 79905, USA.
Tel.: +1.915.543.1009.
E-mail: chad.cooper@ttuhsc.edu

Key words: Castleman’s Disease, Kaposi sarcoma, lymphadenopathy, HHV-8, HIV.

Contributions: the authors contributed equally.

Conflict of interests: the authors declare no potential conflict of interests.

Received for publication: 14 May 2014.
Revision received: 11 June 2014.
Accepted for publication: 13 June 2014.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright L. Ortega et al., 2014
Licensee PAGEPress, Italy
Rare Tumors 2014; 6:5480
doi:10.4081/rt.2014.5480

[page 98] [Rare Tumors 2014; 6:5480]
pain was further described as radiating to both lower extremities and aggravation of the pain with movement such as bending forward and walking with occasional numbness in both lower extremities. He denied any trauma, weakness in his back or lower extremities, saddle anesthesia, urinary or fecal incontinence. His past medical problems include acquired immune deficiency syndrome (AIDS) diagnosed 12 years prior and Kaposi sarcoma.

One year prior to admission he began to develop systemic symptoms such as fever, chills and diffusely swollen lymph nodes. He underwent a fine needle (FNA) aspiration biopsy of right axillary lymph node with pathology revealing the presence of reactive cells for human herpes virus 8. Five months afterwards he had an excisional biopsy of the left inguinal lymph node and a punch skin biopsy that tested positive for Kaposi’s sarcoma. The initial laboratory findings (Table 1) were significant for thrombocytopenia and hypoalbuminemia.

Radiologic imaging was obtained on the day of admission. This included an abdominal computed tomography (CT) (Figure 1) that showed hepatomegaly and diffuse abdominopelvic lymphadenopathy of the retroperitoneal, periaortic, peripancreatic, mesenteric, pelvic, bilateral iliac and inguinal regions. The thoracic and lumbar magnetic resonance imaging (MRI) also revealed diffuse lymphadenopathy of the bilateral supraclavicular, axillary, posterior mediastinal, retrocrural and paraspinal nodes. On the second hospital day the infectious disease con-

| Table 1. Initial laboratory workup. |
|-----------------------------------|
| **Finding** | **Value (range)** |
| White blood cell | 8.50×10³ U/L (4.5-11.0) |
| Hemoglobin | 15.3 g/dL (12.0-15) |
| Hematocrit | 46.2% (36-47) |
| Platelet count | 136×10⁷/uL (150-450) |
| Sodium | 135 mmol/L (135-145) |
| Potassium | 4.1 mmol/L (3.5-5.1) |
| Chloride | 99 mmol/L (98-107) |
| CO2 | 25 mmol/L (21-32) |
| Serum glucose | 106 mg/dL (70-100) |
| BUN | 16 mg/dL (7-22) |
| Creatinine | 0.56 mg/dL (0.60-1.30) |
| Calcium | 9.9 mmol/L (8.5-10.1) |
| Albumin | 3.3 g/dL (3.4-5.0) |
| Protein | 9.8 g/dL (8.5-10.1) |
| AST | 43 U/L (15-37) |
| ALT | 23 U/L (12-78) |
| Alk. Phosphatase | 187 U/L (50-136) |
| IgG | 923 mg/dL (694-1618) |
| IgA | 204 mg/dL (81-463) |
| IgM | 147 mg/dL (46-271) |

BUN, blood urea nitrogen; AST, aspartate-aminotransferase; ALT, alanine-aminotransferase; Ig, immunoglobulin.

![Figure 1. Abdomen/pelvis computed tomography. A) Diffuse abdominopelvic lymphadenopathy (red arrows); B) bilateral inguinal and iliac lymphadenopathy (blue arrows).](image1)

![Figure 2. A) Left supraclavicular lymph node: HHV8+ infected plasma cells in lymph node follicle with CD138 and CD79a immunohistochemistry stains. B) Involved germinal center infiltrated by abnormal plasma cells.](image2)
sult service recommended HAART with Raltegravir 400 mg tablet twice daily and Abacavir/Lamivudine 600/300 mg tablet every day. To determine the immunological status of the patients the HIV viral load was <20 PCR copies/mL. HHV-8 viral load was 25,498 DNA copies/mL, absolute CD4 count was 453 cells/μL (490-1740 cells/μl) and CD8 count was 4142 cells/μl (180-1170 cells/μl). On the fourth hospital day the hematology/oncology consult service was concerned for a plasmablastic lymphoma and therefore recommended a course of chemotherapy. A MRI brain and lumbar puncture with CSF analysis were performed to further evaluate his neurological deficits but both were unremarkable. On the ninth hospital day the excisional biopsy of the left supraclavicular lymph node was performed with pathological findings (Figure 2) of HHV8+ Kaposi sarcoma in the background of multicentric Castleman’s disease (plasmacytic variant). No evidence of transformation into large B-cell or plasmablastic lymphoma was noted. On the twelfth hospital day a bone marrow biopsy was performed with pathological findings of hypercellular marrow demonstrating reactive plasmacytosis with polytypic pattern by kappa and lambda light chains immunostains. On the fifteenth hospital day the patient was discharged home in stable condition on HAART and follow up with the infectious disease and hematology/oncology services for further outpatient management. Chemotherapy with CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) was started and rituximab plus prophylaxis for pneumocystis carinii was included. As an outpatient he received intravenous (IV) cyclophosphamide (750 mg/m² on day 1), IV adriamycin (50 mg/m² on day 1), IV vincristine (1.4 mg/m² on day 1), and oral prednisone (100 mg for 5 days) was administered every month for 4 cycles. The facial droop and ptosis resolved during chemotherapy and the diffuse lymphadenopathy resolved after the complete course of chemotherapy.

Discussion

Multicentric Castleman’s disease has become more relevant in recent years due to its associated with HIV and HHV-8 (Kaposi sarcoma) and its potential to progress into plasmablastic B-cell lymphoma. Dupin et al. reported on the plasmablastic variant of Castleman’s disease being linked to HHV-8-positive plasmablastic lymphoma. A total of 20 patients were analyzed with 8 of these having HIV-1 infection and 12 were HIV negative. Of the 8 HIV-positive patients with MCD, 5 (62.5%) of them also had Kaposi’s sarcoma. Of the patients with HIV infection and MCD HHV-8, 4 (50%) eventually developed a plasmablastic lymphoma and 1 developed a hematological blast crisis 6 months after the diagnosis of MCD. Oksenhendler et al. presented a cohort study of Kaposi sarcoma-associated herpes virus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman’s disease. In this study of HIV-infected patients with MCD, the incidence of NHL was 15-fold higher than that observed in the general HIV-1 infected population. Their data suggests that the development of the MCD also increases the risk of NHL. The plasmablastic NHL likely represents the expansion of plasmablastic microlymphoma from the MCD lesion and progression toward aggressive NHL. The differential diagnosis of HIV-associated MCD should include lymphoma, autoimmune disorders and viral or bacterial infections. Due to the limited amount of data available, it is difficult to make definitive decision regarding the optimal treatment for HHV8 associated MCD. The current options for therapy include chemotherapy, monoclonal antibodies, immune modulators and anti-retroviral therapy. The administration of anti-retroviral therapies has been associated with regression of symptoms in some HIV-infected patients with MCD. The most commonly used chemotherapy regimens for MCD with cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) or cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP). Combination chemotherapy can have a response rate of up to 90%. More aggressive regimen such as CHOP and CVAD can induce durable response in approximately 50% of patients. Most of the data are available on the use of rituximab used either alone or in combination with chemotherapy for first line treatment depending on how aggressiveness of the disease.

Conclusions

In conclusion, the diagnosis of MCD should be considered in patients with HHV-8 (Kaposi’s sarcoma) who present with fever of unknown origin and diffuse lymphadenopathy. The HIV status should always be determined in these cases because it can implicate a different diagnostic, therapeutic, and prognostic approach. Even though MCD occurs with an increased incidence in patients with HIV infection, epidemiologic studies have demonstrated no correlation with CD4 cell count or the use of HAART. A systematic review of all 72 cases of HIV associated MCD published up to 2007 found that 64% of the 48 patients diagnosed with MCD in the HAART era were already on HAART at the time of MCD diagnosis. The progression of MCD to B-cell lymphoma is a concern, especially in patients with HIV infection because it precludes the worst outcome and a high mortality, despite treatment. Hence, further diagnostic evaluation must be performed to rule out this dreadful complication and the early initiation of chemotherapy. The most intriguing part of this case is that MCD occurred in a HIV-positive on HAART and hence a high suspicion is warranted because of the possibly of progression to plasmablastic B-cell lymphoma.

References

1. Reddy D, Mitsuyasu R. HIV-associated multicentric Castleman disease. Curr Opin Oncol 2011;23:475-81.
2. Alkaied H, Harris K, Elsayegh D, et al. Does Kaposi’s sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy? Med Oncol 2012;29:1109-13.
3. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean J Hematol 2012;47:163-77.
4. Mes G, Sipos F, Csomor J, Sreter L. Multicentric Castleman’s disease: a challenging diagnosis. Pathol Oncol Res 2013;19:345-51.
5. Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol 2012;24:76-83.
6. Venkataraman G, Uldrick TS, Aleman K, et al. Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Am J Clin Pathol 2013;139:651-61.
7. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2013;122:4189-98.
8. Dispensieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disease. Am J Hematol 2012;87:997-1002.
9. Dupin N, Dass TL, Kellam P et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12.
10. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-6.
11. Sophie B, Anne-Genevieve M, Nathalie F, et al. The first reported case and management of multicentric Castleman’s disease associated with Kaposi’s sarcoma in an HIV-2-infected patient. AIDS 2007;21:1492-4.
12. Naim F, Fakbouri F, Martins CS, Couto WJ. HIV-associated multicentric Castleman’s disease. Rare Tumors 2012;4:40.
13. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 2010;116:4415-21.